|
Sign In to gain access to subscriptions and/or personal tools.
|
A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies
Richard H. Chapman, MS
Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann{at}hsph.harvard edu)
Patricia W. Stone, RN, MPH, PhD
Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann{at}hsph.harvard edu)
Eileen A. Sandberg, MS, MBA
Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann{at}hsph.harvard edu)
Chaim Bell, MD
Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann{at}hsph.harvard edu)
Peter J. Neumann, ScD
Address correspondence and reprint requests to Dr. Neumann. Harvard Center for Risk Analysis, 718 Huntington Avenue, Boston, MA 02115, telephone (617) 432-1312; fax. (617) 432-0190; e-mail. (pneumann{at}hsph.harvard edu)
Objectives. The authors compiled a comprehensive league table of cost/QALY ratios, and a standardized table of analyses satisfying selected Reference Case criteria from the USPHS Panel on Cost-Effectiveness in Health and Medicine. Methods. They identified 228 cost-utility analyses (CUAs) through literature searches, and abstracted data on methods and cost-utility ratios. The subset of "Panel-worthy" analyses used: a societal or broad health-care perspective, community or patient preference weights, net costs, incremental comparisons, and discounting of costs and QALYs. Results. The 228 CUAs included ratios for 647 interventions, ranging from cost-saving to $52,000,000/QALY (median = $12,000/QALY). The standardized table presents 112 ratios that met the "Panel-worthy" criteria, with articles published in recent years more likely to meet all of the criteria. Conclusions. The comprehensive league table (available on the Web) provides a useful reference, but ratios may not be comparable because of methodologic variations. The standardized table focuses on studies meeting basic methodologic criteria, potentially allowing for better comparison with future Reference Case analyses. Future studies should investigate the quality of analyses' underlying assumptions in addition to whether certain key procedural protocols were met. Key words: cost-utility analysis; league tables; economic evaluation. (Med Decis Making 2000;20:451-467)
Medical Decision Making, Vol. 20, No. 4,
451-458 (2000)
DOI: 10.1177/0272989X0002000409
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. L. Hebert, J. E. Sisk, J. J. Wang, L. Tuzzio, J. M. Casabianca, M. R. Chassin, C. Horowitz, and M. A. McLaughlin
Cost-Effectiveness of Nurse-Led Disease Management for Heart Failure in an Ethnically Diverse Urban Community
Ann Intern Med,
October 21, 2008;
149(8):
540 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-C. T. Shih and M. T. Halpern
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin,
July 1, 2008;
58(4):
231 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gandjour
Changing the Organization of Health Care
JAMA,
July 18, 2007;
298(3):
286 - 286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Skedgel, R. Goeree, S. Pleasance, K. Thompson, B. O'Brien, and D. Anderson
The Cost-Effectiveness of Extended-Duration Antithrombotic Prophylaxis After Total Hip Arthroplasty
J. Bone Joint Surg. Am.,
April 1, 2007;
89(4):
819 - 828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M Bell, D. R Urbach, J. G Ray, A. Bayoumi, A. B Rosen, D. Greenberg, and P. J Neumann
Bias in published cost effectiveness studies: systematic review
BMJ,
March 25, 2006;
332(7543):
699 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Wagmiller, J. J. Griggs, A. W. Dick, and D. M. Sahasrabudhe
Individualized Strategy for Dosing Luteinizing Hormone-Releasing Hormone Agonists for Androgen-Independent Prostate Cancer: Identification of Outcomes and Costs
J. Oncol. Pract,
March 1, 2006;
2(2):
57 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kievit, M. J. Bolster, G. J. van der Wilt, P. Bult, F. B. J. M. Thunnissen, J. Meijer, L. J. A. Strobbe, J. H. G. Klinkenbijl, T. Wobbes, E. M. M. Adang, et al.
Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer
Ann. Onc.,
December 1, 2005;
16(12):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D M Wild, C A Redlich, and A D Paltiel
Surveillance for isocyanate asthma: a model based cost effectiveness analysis
Occup. Environ. Med.,
November 1, 2005;
62(11):
743 - 749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Rosen, D. Greenberg, P. W. Stone, N. V. Olchanski, and P. J. Neumann
Quality of Abstracts of Papers Reporting Original Cost-Effectiveness Analyses
Med Decis Making,
July 1, 2005;
25(4):
424 - 428.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. J. Neumann, A. B. Rosen, D. Greenberg, N. V. Olchanski, R. Pande, R. H. Chapman, P. W. Stone, S. Ondategui-Parra, J. Nadai, J. E. Siegel, et al.
Can We Better Prioritize Resources for Cost-Utility Research?
Med Decis Making,
July 1, 2005;
25(4):
429 - 436.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. A. Brauer, A. B. Rosen, N. V. Olchanski, and P. J. Neumann
Cost-Utility Analyses in Orthopaedic Surgery
J. Bone Joint Surg. Am.,
June 1, 2005;
87(6):
1253 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Lee, C. LeBaron, T. V. Murphy, S. Lett, S. Schauer, and T. A. Lieu
Pertussis in Adolescents and Adults: Should We Vaccinate?
Pediatrics,
June 1, 2005;
115(6):
1675 - 1684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Kanwal, I. M. Gralnek, P. Martin, G. S. Dulai, M. Farid, and B. M.R. Spiegel
Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis
Ann Intern Med,
May 17, 2005;
142(10):
821 - 831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Pirraglia, A. B. Rosen, R. C. Hermann, N. V. Olchanski, and P. Neumann
Cost-Utility Analysis Studies of Depression Management: A Systematic Review
Am J Psychiatry,
December 1, 2004;
161(12):
2155 - 2162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.J. Buxton, S.D. Sullivan, L.F. Andersson, C.J. Lamm, B. Liljas, W.W Busse, S. Pedersen, and K.B. Weiss
Country-specific cost-effectiveness of early intervention with budesonide in mild asthma
Eur. Respir. J.,
October 1, 2004;
24(4):
568 - 574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H-H Konig and J-C Barry
Cost effectiveness of treatment for amblyopia: an analysis based on a probabilistic Markov model
Br J Ophthalmol,
May 1, 2004;
88(5):
606 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Angus, G. Clermont, R. S. Watson, W. T. Linde-Zwirble, R. H. Clark, and M. S. Roberts
Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the United States
Pediatrics,
December 1, 2003;
112(6):
1351 - 1360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Diabetes Prevention Program Research Group
Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes
Diabetes Care,
September 1, 2003;
26(9):
2518 - 2523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Gildea, K. M. Shermock, M. E. Singer, and J. K. Stoller
Cost-Effectiveness Analysis of Augmentation Therapy for Severe {alpha}1-Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med.,
May 15, 2003;
167(10):
1387 - 1392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W Stone, S. Bakken, C. R Curran, and P. H Walker
Evaluation of studies of health economics
Evid. Based Nurs.,
October 1, 2002;
5(4):
100 - 104.
[Full Text]
[PDF]
|
|
|
|
|
|
|
The CDC Diabetes Cost-effectiveness Group
Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes
JAMA,
May 15, 2002;
287(19):
2542 - 2551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S E Gabriel, P Tugwell, and M Drummond
Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology
Ann Rheum Dis,
April 1, 2002;
61(4):
370 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Davidoff
The Heartbreak of Drug Pricing
Ann Intern Med,
June 5, 2001;
134(11):
1068 - 1071.
[Full Text]
[PDF]
|
|
|
|
|
